Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adding, asymptomatic, bilirubin, boceprevir, commensurate, concentrated, concentrating, delivered, discernable, Enanta, faster, ft, hepatotoxicity, illiquid, Inhibitex, innovative, instance, leverage, Maria, outweigh, payer, presence, president, Presidio, progressed, QD, rare, sq, Stahl, strong, telaprevir, Treasurer, undesirable, undetectable, ViiV, week
Removed:
alternative, announced, approvable, Biological, classification, consumption, discontinuation, eligible, ending, enterprise, examine, expansion, extend, Farmaceutica, favor, finalized, generic, Genome, improve, inventory, Ltda, measuring, Medicaid, Microbiologica, notified, opening, optional, put, Quimica, Raymond, receivable, reconciliation, recording, referred, remit, rest, roxythromycin, Schinazi, SciClone, shipped, software, sublicensee, supported, TherapX, thereunder, transition, transitioned, updated
Filing tables
Filing exhibits
- 10-K Annual report
- 10.60 EX-10.60 Employment Letter, Dated December 8, 2010, by and Between the Registrant and Douglas L. Mayers, M.D.
- 10.61 EX-10.61 Employment Letter, Dated December 9, 2010, by and Between the Registrant and David N. Standring, PH.D.
- 10.62 EX-10.62 Employment Letter, Dated November 30, 2010, by and Between the Registrant and Maria Stahl
- 21.1 Exhibit 21.1
- 23.1 EX-23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 EX-31.1 CEO Cert Section 302
- 31.2 EX-31.2 CFO Cert Section 302
- 32.1 EX-32.1 CEO Cert Section 906
- 32.2 EX-32.2 CFO Cert Section 906
Related press release
IDIX similar filings
Filing view
External links
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Idenix Pharmaceuticals, Inc. (the “Company”) for the period ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Daniella Beckman, Interim Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350 as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that, to her knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 7, 2011
/s/ Daniella Beckman | ||
Daniella Beckman | ||
Interim Chief Financial Officer |
A signed original of this written statement required by Section 906 has been provided to Idenix Pharmaceuticals, Inc. and will be retained by Idenix Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.